Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

Research output: Contribution to journalArticle

Abstract

Respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are leading causes of viral lower respiratory tract illness in children and in high-risk adult populations. Despite decades of research, licensed vaccines for RSV and hPIVs do not exist. Recently, however, genetically engineered live attenuated RSV and hPIV candidate vaccines have been generated, several of which are already being evaluated in clinical trials. Recombinant technology allows candidate vaccines to be "fine-tuned" in response to clinical data, which should hasten the development of vaccines against these important respiratory pathogens.

Original languageEnglish (US)
Pages (from-to)1668-1677
Number of pages10
JournalClinical Infectious Diseases
Volume37
Issue number12
DOIs
StatePublished - Dec 15 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines'. Together they form a unique fingerprint.

Cite this